Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
NCT ID: NCT00693199
Last Updated: 2008-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
360 participants
INTERVENTIONAL
2006-07-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
amlodipine
amlodipine 5mg once daily for 28 days
2
terazosin
terazosin 2 mg once daily for 28 days
3
amlodipine plus terazosin
amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amlodipine
amlodipine 5mg once daily for 28 days
terazosin
terazosin 2 mg once daily for 28 days
amlodipine plus terazosin
amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. with LUTS \[defined as International Prostate Symptom Score (IPSS) \>= 10\].
3. Stage 1 or 2 essential hypertension (SBP \>= 140 mm Hg and \< 180 mm Hg and/or DBP \>= 90 mm Hg and \< 110 mm Hg)
Exclusion Criteria
2. Secondary hypertension
3. Prostate cancer
4. Prostate surgery or other intervention
5. Use of any agents to influence the LUTS symptoms in the last 4 weeks
6. Other severe diseases
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Science and Technology of China
OTHER
Peking University First Hospital
OTHER
Anhui Medical University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ping Liu, PhD
Role: STUDY_DIRECTOR
Biomedical Institute of Anhui Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biomedicine Inistitute of Anhui Medical University
Hefei, Anhui, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu H, Liu P, Mao G, Chen G, Wang B, Qin X, Na Y, Liu Z, Wang X, Xu X. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. Urology. 2009 Jul;74(1):130-6. doi: 10.1016/j.urology.2008.11.051. Epub 2009 Apr 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMI-AT-02
Identifier Type: -
Identifier Source: org_study_id